Events

SHERIDAN, WYOMING – May 6, 2025 – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has announced key updates to its Supervisory Board composition and committee leadership ahead of its Annual General Meeting (AGM) scheduled for May 8, 2025. The adjustments, prompted by recent executive developments, aim to reinforce strategic governance while maintaining alignment with shareholder interests and regulatory best practices.

Strategic Governance Realignment Following CEO Nomination

Philips previously disclosed the proposal to appoint Bob White, a seasoned executive in health technology, to the Supervisory Board during the AGM. Mr. White, born in 1962 and of American nationality, was initially set to chair the Quality & Regulatory (Q&R) Committee. However, following his recent nomination to become Chief Executive Officer of Olympus Corporation, a shift in responsibilities has been agreed upon.

SHERIDAN, WYOMING – May 6, 2025 – St. Luke’s University Health Network has announced a landmark investment of over $30 million in GE HealthCare’s advanced Magnetic Resonance Imaging (MRI) technology, reinforcing its commitment to cutting-edge diagnostic innovation and enhanced patient care. This strategic move by the Bethlehem, Pennsylvania-based nonprofit healthcare network is aimed at expanding access to faster, more precise imaging while significantly improving patient comfort and operational efficiency.

Driving Precision and Efficiency Across the Network

SHERIDAN, WYOMING – May 6, 2025 – GE HealthCare (Nasdaq: GEHC) has reported a strong start to 2025 with notable revenue and profit gains in the first quarter, signaling resilience amid global trade complexities and bolstering its long-term value proposition through innovation and strategic acquisitions.

The company achieved a 3% year-over-year increase in total revenue to $4.8 billion, with organic revenue growth reaching 4%. Net income rose to $564 million from $374 million a year earlier, pushing the net income margin to 11.8%, up from 8.0%. Adjusted EBIT margin also improved slightly to 15.0%, reflecting strong operational execution and productivity improvements.

Strong Performance Across Key Financial Indicators

SHERIDAN, WYOMING – May 6, 2025 – GE HealthCare (Nasdaq: GEHC) has announced a strategic expansion of its radiation oncology solutions, unveiling a suite of AI-driven technologies at the ESTRO 2025 Congress in Vienna, Austria. These developments are designed to streamline oncology workflows, accelerate treatment timelines, and improve clinical outcomes—addressing critical priorities in modern cancer care.

With cancer continuing to rank among the world’s leading causes of death, GE HealthCare is positioning itself at the forefront of oncology innovation. The company’s new solutions—ranging from AI-enabled organ segmentation to advanced MR-only radiotherapy workflows—aim to equip clinicians with tools that improve efficiency, precision, and personalization in treatment planning.

Strategic Portfolio Expansion with Spectronic Medical Acquisition

SHERIDAN, WYOMING – May 6, 2025 – GE HealthCare (Nasdaq: GEHC) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Aurora dual-head SPECT/CT system and Clarify DL, a Deep Learning-powered image reconstruction solution. This milestone underscores GE HealthCare’s commitment to advancing nuclear medicine by offering solutions that drive diagnostic precision, streamline workflows, and support evolving clinical needs.

University Hospitals in Cleveland, Ohio, has become the first healthcare system in the United States to install the Aurora system. This strategic deployment reflects growing demand among providers for scalable imaging technologies that support a wide range of clinical applications while enabling a more personalized approach to patient care.

SHERIDAN, WYOMING – May 5, 2025 – Siemens Healthineers has introduced its Magnetom Flow RT Pro Edition at the European Society for Radiotherapy and Oncology (ESTRO) 2025, marking a significant innovation in magnetic resonance imaging (MRI) tailored for radiation therapy. Designed for operational flexibility and clinical precision, the 1.5 Tesla system addresses longstanding challenges in integrating MRI within radiation oncology environments while offering sustainability and workflow advantages.

Revolutionizing MRI Accessibility in Radiotherapy Settings

SHERIDAN, WYOMING – May 5, 2025 – Siemens Healthineers and Klinikum Region Hannover (KRH) have jointly launched an advanced Infection Control System (ICS) at KRH Klinikum Siloah, a leading regional hospital in Hannover, Germany. The strategic implementation marks a significant move toward reducing hospital-acquired infections (HAIs), improving hygiene standards, and safeguarding both patient and staff well-being across the facility.

Combatting Nosocomial Infections with Innovation

Hospital-acquired infections continue to place immense strain on healthcare systems worldwide. In Germany alone, the Robert Koch Institute reported approximately 600,000 nosocomial infections in 2019, with around 20,000 associated deaths. Multi-resistant germs—responsible for a substantial share of such infections—led to an estimated five million global deaths in 2021. The World Health Organization anticipates this number could double by 2050.

SHERIDAN, WYOMING – May 5, 2025 – Tower Health and Siemens Healthineers have entered a decade-long Value Partnership designed to modernize diagnostic imaging capabilities, enhance operational efficiency, and support long-term clinical excellence across the Tower Health network. The multi-faceted alliance marks a strategic investment in state-of-the-art technology and digital tools aimed at elevating patient care in radiology, oncology, and cardiology services.

Driving Long-Term Value Through Technological Modernization

The 10-year Value Partnership is more than a procurement agreement; it is a strategic roadmap to elevate Tower Health’s infrastructure through lifecycle management and standardization of advanced imaging equipment. The collaboration will bring cutting-edge Siemens Healthineers solutions to Tower Health, including:

SHERIDAN, WYOMING – May 5, 2025 – Johnson & Johnson MedTech has announced encouraging 3-month results from its pivotal Omny-IRE clinical trial, spotlighting the high-performance capabilities of its investigational OMNYPULSE™ Platform. Unveiled during the 2025 Heart Rhythm Society (HRS) Annual Meeting and simultaneously published in JACC Clinical Electrophysiology, the findings mark a strategic milestone in the company’s pulsed field ablation (PFA) portfolio expansion, with significant implications for patient care, procedural efficiency, and technology adoption in electrophysiology.

Breakthrough Results from the Omny-IRE Trial

SHERIDAN, WYOMING – May 5, 2025 – Johnson & Johnson MedTech has announced the presentation of 22 sponsored or funded clinical studies at the Heart Rhythm Society (HRS) 2025 Annual Meeting in San Diego, showcasing its continued leadership in the electrophysiology space. The company’s expansive dataset highlights innovation in pulsed field ablation (PFA) technologies, real-world treatment strategies, and critical insights from the REAL-AF Registry and Patient Care Pathways and Outcomes study—reinforcing its commitment to evidence-based care and better patient outcomes.

Driving Strategic Innovation in Cardiac Electrophysiology

SHERIDAN, WYOMING – May 5, 2025 – Johnson & Johnson MedTech has marked a significant milestone in the evolution of robotic-assisted surgery by completing the first clinical trial cases of its OTTAVA™ Robotic Surgical System. This development positions the company at the forefront of innovation in minimally invasive procedures, reinforcing its strategic commitment to delivering cutting-edge surgical technologies that raise standards in operating rooms worldwide.

Strategic Leap in Robotic-Assisted Surgery

The inaugural clinical cases for the OTTAVA system were led by Dr. Erik Wilson, Chief of Minimally Invasive and Elective General Surgery at UT Health Houston, who performed Roux-en-Y gastric bypass surgeries at Memorial Hermann-Texas Medical Center. These procedures represent the first real-world clinical application of the OTTAVA system and a pivotal moment in its developmental journey.

SHERIDAN, WYOMING – May 5, 2025 – Shockwave Medical, Inc., a Johnson & Johnson MedTech company and global leader in circulatory restoration, has officially initiated its FORWARD CAD Investigational Device Exemption (IDE) study. This pivotal research effort will evaluate the safety and efficacy of the Shockwave Javelin Coronary IVL Catheter for the treatment of difficult-to-cross, heavily calcified coronary artery lesions—an area with high unmet clinical need and procedural risk.

The first patient in the study was successfully treated by Dr. Evan Shlofmitz and Dr. Ziad Ali at St. Francis Hospital & The Heart Center in Roslyn, New York. This milestone underscores the growing clinical interest in Shockwave’s forward IVL (intravascular lithotripsy) platform as a potential alternative to atherectomy, especially in complex percutaneous coronary interventions (PCI).

Advancing Treatment for Challenging Coronary Artery Disease

SHERIDAN, WYOMING – May 5, 2025 – Medtronic plc (NYSE: MDT), a global leader in healthcare technology, has received U.S. Food and Drug Administration (FDA) approval for its Simplera Sync™ sensor, marking a significant expansion of its continuous glucose monitoring (CGM) portfolio in the United States. The approval enables integration of the Simplera Sync™ sensor with the company’s flagship MiniMed™ 780G system, offering greater flexibility and convenience to people managing diabetes through advanced insulin delivery technology.

Strategic Advancement in Diabetes Care Technology

SHERIDAN, WYOMING – May 5, 2025 – Medtronic plc (NYSE: MDT), a global leader in healthcare technology, has officially submitted 510(k) applications to the U.S. Food and Drug Administration (FDA) for its MiniMed™ 780G pump and SmartGuard™ algorithm, paving the way for seamless integration with Abbott’s advanced continuous glucose monitoring (CGM) platform. This critical regulatory milestone strengthens Medtronic’s strategic partnership with Abbott and positions the company to deliver more interoperable, intelligent diabetes care solutions to the U.S. market.

Accelerating Innovation Through Strategic Interoperability

SHERIDAN, WYOMING – May 5, 2025 – Medtronic plc (NYSE: MDT), a global leader in healthcare technology, has received U.S. Food and Drug Administration (FDA) approval for the OmniaSecure™ defibrillation lead—the smallest-diameter, catheter-delivered defibrillation lead for right ventricular implantation. This approval marks a major advancement in cardiac rhythm management, offering physicians a less invasive, highly durable solution to treat life-threatening arrhythmias in both adults and adolescents with smaller anatomies.

Strategic Advancement in Cardiac Rhythm Management

The FDA’s green light for the OmniaSecure lead strengthens Medtronic’s leadership in electrophysiology and expands its robust portfolio of transvenous lead solutions. At only 4.7 French (1.6mm) in diameter, the OmniaSecure lead builds on the proven SelectSecure™ Model 3830 pacing lead platform, already widely adopted in the clinical community for over two decades.

SHERIDAN, WYOMING – May 5, 2025 – Medtronic has announced a major milestone for its Hugo™ robotic-assisted surgery (RAS) system, as the Expand URO U.S. clinical trial met both primary safety and effectiveness endpoints. The results position the company for strategic market entry into the U.S. robotic-assisted surgery sector, the largest of its kind globally, and were presented as a late-breaking session at the American Urologic Association (AUA) annual meeting in Las Vegas.

Landmark Trial Sets New Benchmark in Robotic Urologic Surgery

The Expand URO study is the largest Investigational Device Exemption (IDE) trial conducted in the U.S. for multi-port robotic-assisted urologic procedures. Designed as a prospective, multi-center, single-arm study, it involved 137 patients across six hospitals. Participants underwent one of three common urologic surgeries — prostatectomy, nephrectomy, or cystectomy — using the Hugo RAS system.

SHERIDAN, WYOMING – May 5, 2025 – Medtronic plc (NYSE: MDT) has announced encouraging one-year clinical outcomes for its investigational Affera™ pulsed field ablation (PFA) technologies, reinforcing its strategic leadership in arrhythmia management. The results—revealed at the Heart Rhythm Society 2025 Annual Meeting—highlight the performance of the next-generation Sphere-360™ single-shot PFA catheter and the dual-energy Sphere-9™ catheter in treating patients with paroxysmal and persistent atrial fibrillation (AFib), one of the world’s most prevalent cardiac rhythm disorders.

Sphere-360™ Demonstrates Safety, Efficiency, and Superior Mapping Integration

The Sphere-360 catheter, part of the Affera ecosystem, is engineered as a single-shot PFA mapping and ablation tool designed specifically for paroxysmal AFib. In a European-based, multi-center clinical trial, the technology achieved:

SHERIDAN, WYOMING - May 5, 2025 - In the evolving landscape of restorative dentistry, post-endodontic restoration has emerged as a cornerstone of long-term tooth preservation strategies, offering clinicians and patients alike a pathway to restore function, aesthetics, and durability following root canal therapy. New insights from recent clinical literature highlight the increasing relevance of this specialized restorative approach for practitioners focused on optimizing patient outcomes and return on investment in dental care.

Driving Longevity Through Strategic Restoration

SHERIDAN, WYOMING - May 5, 2025 - In a dental landscape increasingly dominated by minimally invasive approaches, orthognathic surgery-supported by pre- and post-surgical orthodontics-is regaining prominence as a critical solution for addressing complex skeletal deformities that fall beyond the scope of traditional orthodontics.

This resurgent interest is not merely cosmetic. When aesthetic, functional, and long-term stability outcomes are considered, orthognathic surgery emerges as a high-ROI treatment path for select cases. It effectively bridges orthodontic limitations by offering predictable, stable results where skeletal discrepancies compromise both occlusion and facial harmony.

Orthognathic Surgery: A Modern Answer to Structural Challenges

SHERIDAN, WYOMING - May 5, 2025 - The integration of digital technology in dentistry is revolutionizing how dental professionals approach aesthetic treatments, offering enhanced predictability, improved patient engagement, and cross-disciplinary collaboration-while also presenting operational and financial challenges for broader adoption.

Once a futuristic concept, digital dentistry has now become a foundational component in modern dental practices. With advanced software tools like Digital Smile Design (DSD) and the Digital Smile System enabling highly personalized smile simulations, the field is experiencing a strategic shift that enhances both patient outcomes and clinical efficiency.

Transforming Smile Design Through Digital Innovation